FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of the formula
or pharmaceutically acceptable salts thereof, which can be used to prevent, and/or inhibit, and/or treat cancer. In formula (I) A and A' independently represent phenyl or pyridylene group; R2 represents a hydrogen or alkyl group (C1-C4); R3 represents a 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 2-pyrimidinyl group, 4-pyrimidinyl group or 5-pyrimidinyl group; R4 represents a carbonyl group or sulfonyl group; R5 is a -NH-(CH2)(a)-NR6R7 group or a 4-methylpiperazinyl group and a is an integer from 1 to 4, R6 and R7 independently represent a nalkyl group (C1-C4) or R6 R7 together with nitrogen atom they are bounded to form a heterocyclic group selected from 4-methylpiperazinyl group, morpholine group, pyrrolidinyl group and piperidine group. The invention also relates to a method for preparation of compounds of formula (I) and a pharmaceutical composition containing them.
EFFECT: improved compounds properties.
16 cl, 6 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2020 |
|
RU2821414C2 |
ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2019 |
|
RU2815493C2 |
MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
FLT3 RECEPTOR ANTAGONISTS | 2015 |
|
RU2710928C2 |
ADAMANTYL DERIVATIVES USEFUL FOR TREATMENT OF JNK-MEDIATED DISORDER | 2012 |
|
RU2626890C2 |
SUBSTITUTED DIALKYL (OXIDE)-Λ-SULFANILIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2711749C2 |
ACTIVE COMPOUNDS WITH RESPECT TO BROMO-DOMAINS | 2015 |
|
RU2743074C2 |
SULFONYL UREA AND RELATED COMPOUNDS AND USE THEREOF | 2016 |
|
RU2739356C2 |
NEW DERIVATIVES OF HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR MODULATION OF AUTOIMMUNE DISEASES, METHOD FOR PREPARING THESE COMPOUNDS | 2000 |
|
RU2255937C2 |
SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
Authors
Dates
2018-01-19—Published
2013-09-30—Filed